Trial · NCT06766019
Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer
NCT06766019, Phase 2, Active not recruiting, The First Affiliated Hospital with Nanjing Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer. Trials, record NCT06766019. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06766019
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer
- NCT number
- NCT06766019
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 47 participants, estimated
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Conditions
- Pancreatic Cancer
- Interventions
- Adebrelimab combined with irinotecan liposomal (II), oxaliplatin, and 5-FU/LV
- First posted
- 2025-01-09
- Last updated
- 2025-01-09
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Surgical conversion rate | Up to 6 months | Refers to the proportion of subjects with successful conversion to all subjects receiving conversion therapy. Achievement of R0/R1 resection after conversion therapy was defined as successful conversion. |
| Secondary | Overall Survival (OS) | 5 years | Time from start of patient treatment to death from any cause |
| Secondary | 1-year OS rate | 1 year | Proportion of subjects who have survived 1 year from the date of first treatment after enrollment to all treated subjects |
| Secondary | Objective response rate (ORR) | Up to 3 years | Proportion of subjects including complete response (CR) or partial response (PR) |
| Secondary | Event-free survival (EFS) | Up to 3 years | The EFS endpoint is a composite time-to-event endpoint, and the "treatment failure" event is defined as the earliest occurrence of the following events: a. Failure to achieve local disease-free status after completion of conversion therapy and/or surgery (i.e., failed resection or disease progression resulting in inoperability); b. Local or distant recurrence; c. Death; |
| Secondary | Disease Control Rate (DCR) | Up to 3 years | Proportion of subjects whose best response observed throughout the study was CR, PR, or stable disease (SD) |
| Secondary | Duration of response (DoR) | Up to 3 years | From the first tumor response (CR or PR) to disease progression (PD) or death (whichever occurs earlier) |
| Secondary | Time to disease progression (TTP) | Up to 3 years | The time from the date of enrollment to the first observation of PD |
| Other | Treatment-related adverse events | Up to 3 years | Observe all patients for any adverse events during the clinical study, including abnormalities in clinical symptoms and vital signs, abnormalities in laboratory tests, record their clinical manifestation characteristics, severity, time of occurrence, duration, treatment methods and prognosis, and determine their correlation with the investigational drug. |
| Other | CA19-9 Response Rate | Up to 3 years | Tumor marker response rates were assessed by changes in CA19-9 serum concentrations. Tumor marker response was defined as at least one concentration reduction of at least 50% from baseline occurring during the course of treatment. Only subjects with baseline values greater than the upper detection limit will be included in the evaluation of tumor marker response. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06766019
GET https://conductscience.org/api/trials/v1/NCT06766019/registered